Sonnet BioTherapeutics Holdings Management
Management criteria checks 3/4
Sonnet BioTherapeutics Holdings' CEO is Raghu Rao, appointed in Apr 2025, has a tenure of less than a year. directly owns 0.077% of the company’s shares, worth $3.20K. The average tenure of the management team and the board of directors is 4.2 years and 5.6 years respectively.
Key information
Raghu Rao
Chief executive officer
US$120.8k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.08% |
| Management average tenure | 4.2yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement
Oct 04Sonnet BioTherapeutics announces 1-for-14 reverse stock split
Sep 16Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Jul 22We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Dec 19
CEO
Raghu Rao (61 yo)
less than a year
Tenure
US$120,828
Compensation
Mr. Raghu Rao serves as Venture Partner at Bridge Point Capital. He serves as Interim CEO & Director at Sonnet BioTherapeutics Holdings, Inc. since April 2025 and had been its Independent Director since No...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Director | less than a year | US$120.83k | 0.077% $ 3.2k | |
| Chief Scientific Officer & Co-Founder | 10.3yrs | US$419.66k | 0.069% $ 2.9k | |
| CFO, Financial Controller & Director | 6.3yrs | US$93.94k | 0.012% $ 509.9 | |
| President & Chief Business Officer | less than a year | no data | 0.00072% $ 30.0 | |
| Chief Operating Officer | no data | no data | no data | |
| Chief Technical Officer | 5.1yrs | no data | no data | |
| Chief Medical Officer | 4.1yrs | no data | no data | |
| Head of Clinical Operations | 4.2yrs | no data | no data |
4.2yrs
Average Tenure
69yo
Average Age
Experienced Management: SONN's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Director | 5.5yrs | US$120.83k | 0.077% $ 3.2k | |
| CFO, Financial Controller & Director | 10.1yrs | US$93.94k | 0.012% $ 509.9 | |
| Independent Director | 2.7yrs | US$64.33k | 0.013% $ 535.8 | |
| Independent Director | 5.6yrs | US$59.83k | 0.018% $ 730.5 | |
| Independent Director | 6.8yrs | US$58.33k | 0.018% $ 743.8 |
5.6yrs
Average Tenure
61yo
Average Age
Experienced Board: SONN's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 06:23 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sonnet BioTherapeutics Holdings, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |